|本期目录/Table of Contents|

[1]翁飞鸿,周一平,伊思敏,等.肝纤维化的病理学发生机制及诊疗研究进展[J].天津医科大学学报,2023,29(05):559-563.
点击复制

肝纤维化的病理学发生机制及诊疗研究进展(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
29卷
期数:
2023年05期
页码:
559-563
栏目:
综述
出版日期:
2023-09-20

文章信息/Info

Title:
-
文章编号:
1006-8147（2023）05-0559-05
作者:
翁飞鸿; 周一平; 伊思敏; 李卫东
（天津医科大学基础医学院遗传学系，天津300070）
Author(s):
-
关键词:
肝纤维化; 炎症; 上皮-间充质转化; 导管反应; 脂噬
Keywords:
-
分类号:
R364.3+3
DOI:
-
文献标志码:
A
摘要:
肝纤维化是慢性肝病引起的失代偿表现。尽管各类病因引起肝纤维化的发病过程不尽相同，但它们仍然遵循肝细胞损伤→免疫炎症激活→肝星状细胞（HSCs）活化→细胞外基质（ECM）过度沉积→结构功能损伤的基本病理学改变。本文将从病理学改变角度出发，以致病因素、发病机制（免疫炎症激活机制、细胞转化机制、脂噬与自噬机制）、诊疗进展为主线，叙述肝纤维化的发病过程和调控机制，并阐述相关诊疗进展，旨在帮助人们了解肝纤维化病理学发病过程和诊疗方向。
Abstract:
-

参考文献/References:

[1] GINS P，KRAG A，ABRALDES J G，et al. Liver cirrhosis[J]. Lancet，2021，398（10308）：1359-1376.
[2] MOON A M，SINGAL A G，TAPPER E B. Contemporary epidemiology of chronic liver disease and cirrhosis[J]. Clin Gastroenterol Hepatol，2020，18（12）：2650-2666.
[3] PAIK J M，GOLABI P，YOUNOSSI Y，et al. Changes in the global burden of chronic liver diseases from 2012 to 2017：the growing impact of NAFLD[J]. Hepatology，2020，72（5）：1605-1616.
[4] SMITH A，BAUMGARTNER K，BOSITIS C. Cirrhosis：diagnosis and management [J]. Am Fam Physician，2019，100（12）：759-770.
[5] LI T Y，YANG Y，ZHOU G，et al. Immune suppression in chronic hepatitis B infection associated liver disease：a review[J]. World J Gastroenterol，2019，25（27）：3527-3537.
[6] KHATUN M，RAY R B. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis[J]. Cells，2019，8（10）：1249.
[7] KUMAR S，DUAN Q，WU R，et al. Pathophysiological communication between hepatocytes and non-parenchymal cells in liver injury from NAFLD to liver fibrosis[J]. Adv Drug Deliv Rev，2021，176：113869.
[8] SOTO-ANGONA ?譫，ANMELLA G，VALDéS-FLORIDO M J，et al. Non-alcoholic fatty liver disease（NAFLD） as a neglected metabolic companion of psychiatric disorders：common pathways and future approaches[J]. BMC Med，2020，18（1）：261.
[9] SATO K，MARZIONI M，MENG F，et al. Ductular reaction in liver diseases：pathological mechanisms and translational significances[J]. Hepatology，2019，69（1）：420-430.
[10] YU K，LI Q，SHI G，et al. Involvement of epithelial-mesenchymal transition in liver fibrosis[J]. Saudi J Gastroenterol，2018，24（1）：5-11.
[11] FILALI-MOUNCEF Y，HUNTER C，ROCCIO F，et al. The ménage à trois of autophagy，lipid droplets and liver disease[J]. Autophagy，2022，18（1）：50-72.
[12] SHOJAIE L，IORGA A，DARA L. Cell death in liver diseases：a review [J]. Int J Mol Sci，2020，21（24）：9682.
[13] PEISELER M，SCHWABE R，HAMPE J，et al. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease-novel insights into cellular communication circuits[J]. J Hepatol，2022，77（4）：1136-1160.
[14] CHEN C，YANG R X，XU H G. STING and liver disease[J]. J Gastroenterol，2021，56（8）：704-712.
[15] KISSELEVA T，BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol，2021，18（3）：151-166.
[16] BERINGER A，MIOSSEC P. IL-17 and TNF-α co-operation contributes to the proinflammatory response of hepatic stellate cells [J]. Clin Exp Immunol，2019，198（1）：111-120.
[17] DEWIDAR B，MEYER C，DOOLEY S，et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019[J]. Cells，2019，8（11）：1419.
[18] ZUO L，ZHU Y，HU L，et al. PI3-kinase/Akt pathway-regulated membrane transportation of acid-sensing ion channel 1a/calcium ion influx/endoplasmic reticulum stress activation on PDGF-induced HSC activation[J]. J Cell Mol Med，2019，23（6）：3940-3950.
[19] GROHMANN M，WIEDE F，DODD G T，et al. Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC[J]. Cell，2018， 175（5）：1289-1306.
[20] FABREGAT I，CABALLERO-D?魱AZ D. Transforming growth factor-β-induced cell plasticity in liver fibrosis and hepatocarcinogenesis [J]. Front Oncol，2018，8：357.
[21] OH S H，SWIDERSKA-SYN M，JEWELL M L，et al. Liver regeneration requires Yap1-TGFβ-dependent epithelial-mesenchymal transition in hepatocytes [J]. J Hepatol，2018，69（2）：359-367.
[22] FOGLIA B，CANNITO S，BOCCA C，et al. ERK pathway in activated，myofibroblast-like，hepatic stellate cells：a critical signaling crossroad sustaining liver fibrosis [J]. Int J Mol Sci，2019，20（11）：2700.
[23] DHINGRA S，MAHADIK J D，TARABISHY Y，et al. Prevalence and clinical significance of portal inflammation，portal plasma cells，interface hepatitis and biliary injury in liver biopsies from patients with non-alcoholic steatohepatitis [J]. Pathology，2022，54（6）：686-693.
[24] KYRITSI K，KENNEDY L，MEADOWS V，et al. Mast cells induce ductular reaction mimicking liver injury in mice through mast cell-derived transforming growth factor beta 1 signaling[J]. Hepatology，2021，73（6）：2397-2410.
[25] CHEN Y，GAO W K，SHU Y Y，et al. Mechanisms of ductular reaction in non-alcoholic steatohepatitis[J]. World J Gastroenterol，2022，28（19）：2088-2099.
[26] PLANAS-PAZ L，SUN T，PIKIOLEK M，et al. YAP，but not RSPO-LGR4/5，signaling in biliary epithelial cells promotes a ductular reaction in response to liver injury[J]. Cell Stem Cell，2019，25（1）：39-53.
[27] ZHAO Y，YE W，WANG Y D，et al. HGF/c-Met：a key promoter in liver regeneration [J]. Front Pharmacol，2022，13：808855.
[28] LUCANTONI F，MARTíNEZ-CEREZUELA A，GRUEVSKA A，et al. Understanding the implication of autophagy in the activation of hepatic stellate cells in liver fibrosis：are we there yet? [J]. J Pathol，2021，254（3）：216-228.
[29] SCHWABE R F，LUEDDE T. Apoptosis and necroptosis in the liver：a matter of life and death[J]. Nat Rev Gastroenterol Hepatol，2018，15（12）：738-752.
[30] VISALLI M，BARTOLOTTA M，POLITO F，et al. miRNA expression profiling regulates necroptotic cell death in hepatocellular carcinoma [J]. Int J Oncol，2018，53（2）：771-780.
[31] ZHENG M，TIAN Z. Liver-mediated adaptive immune tolerance [J]. Front Immunol，2019，10：2525.
[32] JOSEPH J. Serum marker panels for predicting liver fibrosis - an update [J]. Clin Biochem Rev，2020，41（2）：67-73.
[33] PATERNOSTRO R，TRAUNER M. Current treatment of non-alcoholic fatty liver disease[J]. J Intern Med，2022，292（2）：190-204.
[34] KUMAR V，XIN X，MA J，et al. Therapeutic targets，novel drugs，and delivery systems for diabetes associated NAFLD and liver fibrosis[J]. Adv Drug Deliv Rev，2021，176：113888.
[35] ZHAO M，WANG L，WANG M，et al. Targeting fibrosis，mechanisms and cilinical trials[J]. Signal Transduct Target Ther，2022，7（1）：206.
[36] TAKEUCHI S，TSUCHIYA A，IWASAWA T，et al. Small extracellular vesicles derived from interferon-γ pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis[J]. NPJ Regen Med，2021，6（1）：19.
[37] HU C，WU Z，LI L. Mesenchymal stromal cells promote liver regeneration through regulation of immune cells [J]. Int J Biol Sci，2020，16（5）：893-903.
[38] BRUNO S，CHIABOTTO G，CAMUSSI G. Extracellular vesicles：a therapeutic option for liver fibrosis[J]. Int J Mol Sci，2020，21（12）：4255.

相似文献/References:

[1]刘文东,李英娴,娄婷婷,等.青蒿琥酯对肝纤维化大鼠肝组织基质金属蛋白酶表达的影响[J].天津医科大学学报,2013,19(05):362.
[2]马晓芳,童静凯,牛文彦.肥胖和缺氧对小鼠原代脂肪细胞分泌TNFα的影响[J].天津医科大学学报,2014,20(01):1.
　MA Xiao-fang,TONG Jing-kai,NIU Wen-yan.Effect of obesity and hypoxia on TNFa secretion by primary adipocytes in mice[J].Journal of Tianjin Medical University,2014,20(05):1.
[3]徐亚洁,张晓燕,马淑晶,等.神经酰胺对肝纤维化治疗作用的初步研究[J].天津医科大学学报,2014,20(04):260.
　XU Ya-jie,ZHANG Xiao-yan,MA Shu-jing,et al.Effects of ceramide on hepatic fibrosis[J].Journal of Tianjin Medical University,2014,20(05):260.
[4]张晓燕,马淑晶,徐亚洁,等.青蒿琥酯对人源肝星状细胞LX-2增殖、胶原产生以及KLF6表达的影响[J].天津医科大学学报,2014,20(04):257.
　ZHANG Xiao-yan,MA Shu-jing,XU Ya-jie,et al.Effects of artesunate on cell proliferation，collagen generated and KLF6 expression in hepatic stellate cells[J].Journal of Tianjin Medical University,2014,20(05):257.
[5]李萌乾,王青松,郭正隆,等.诱导型狨猴肝纤维化模型的建立 [J].天津医科大学学报,2014,20(06):433.
　LI Meng-qian,WANG Qing-song,GUO Zheng-long,et al. Establishment of drug-induced common marmoset model for hepatic fibrosis[J].Journal of Tianjin Medical University,2014,20(05):433.
[6]崔占前,徐延敏.脂蛋白相关性磷脂酶A2及高敏C反应蛋白与左心房内径的关系[J].天津医科大学学报,2015,21(03):196.
　CUI Zhan-qian,XU Yan-min.Relationship between plasma lipoprotein-associated phospholipase A2, high sensitivity C reactive protein and left atrial diameter[J].Journal of Tianjin Medical University,2015,21(05):196.
[7]陈雅婧,王 勇 综述,刘运德,等.C1QBP的多种配体及其在感染和炎症中的研究进展[J].天津医科大学学报,2016,22(01):84.
[8]赵一贺,张 畅,牛文彦.电脉冲刺激的骨骼肌细胞条件培养基逆转内皮细胞胰岛素抵抗和功能障碍[J].天津医科大学学报,2017,23(01):1.
　ZHAO Yi-he,ZHANG Chang,NIU Wen-yan.Conditional medium from electric pulse-stimulated C2C12 skeletal muscle cells reverses insulin resistance and endothelial dysfunction in endothelial cells[J].Journal of Tianjin Medical University,2017,23(05):1.
[9]刘 悦,李杉杉,唐诗慧,等.蒿鳖养阴软坚方通过激活Nrf2/NQO1信号通路抑制肝纤维化发生[J].天津医科大学学报,2018,24(01):19.
　LIU Yue,LI Shan-shan,TANG Shi-hui,et al.Effects of HaobieYangyinRuanjian on inhibition of hepatic fibroesis through upregulated Nrf2/NQO1 pathway[J].Journal of Tianjin Medical University,2018,24(05):19.
[10]卢娜,方步武.蒿鳖养阴软坚方对刀豆球蛋白A诱导的肝纤维化Nrf2/HO-1信号通路影响[J].天津医科大学学报,2018,24(02):112.
　LU Na,FANG Bu-wu.Effect of Haobie yangyin ruanjian prescription on Nrf2/HO-1 signaling pathway in ConA-induced hepatic fibrosis[J].Journal of Tianjin Medical University,2018,24(05):112.
[11]刘志杰综述,詹江华审校.肝巨噬细胞在胆道闭锁肝纤维化中的作用[J].天津医科大学学报,2023,29(04):453.

备注/Memo

备注/Memo:
基金项目 国家自然科学基金资助项目（92046014）
作者简介 翁飞鸿（2001-），男，学士在读；通信作者：李卫东，E-mail：liweidong98@tum.edu.cn。
更新日期/Last Update: 2023-09-25